淋巴细胞最低值与食管癌放化疗后生存结局
该研究纳入504例I-III期食管癌患者,分析放化疗期间绝对淋巴细胞计数(ALC)最低值与生存的关系。结果显示4级ALC最低值发生率为27%,且与更差的总生存和疾病特异性生存显著相关;放疗类型等可预测4级最低值。
要点
- 放化疗期间4级淋巴细胞最低值发生率为27%,与更差生存显著相关。
- 远端肿瘤位置、根治性放化疗、紫杉烷/5-氟尿嘧啶化疗及光子放疗可预测4级最低值。
- 放疗类型通过影响平均身体剂量暴露而影响4级最低值风险。
核心结论
- 食管癌放化疗期间4级淋巴细胞最低值与不良生存结局相关,提示宿主免疫在疾病控制中可能发挥作用。
研究设计与样本
- 回顾性分析504例I-III期食管癌患者(2007-2013年),接受新辅助或根治性放化疗,每周检测绝对淋巴细胞计数。
主要发现
- 中位随访36个月,放化疗期间1、2、3、4级淋巴细胞最低值发生率分别为2%、12%、59%、27%。
- 多因素分析显示4级淋巴细胞最低值与更差的总生存和疾病特异性生存显著相关。
- 4级最低值的预测因素包括远端肿瘤位置、根治性放化疗、紫杉烷/5-氟尿嘧啶化疗及光子放疗(对比质子放疗)。
- 放疗类型强烈影响平均身体剂量暴露,后者是4级最低值的强预测因素(每戈瑞比值比1.22,P<.001)。
关键数值与推荐
- 淋巴细胞最低值分级依据常见不良事件评价标准(CTCAE)4.0版。
临床怎么用
- 放化疗期间应关注淋巴细胞最低值,4级最低值提示预后不良。
- 选择化疗方案和放疗类型时需考虑对宿主免疫的影响,可优先选择免疫影响较小的策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Host immunity may affect the outcome in patients with esophageal cancer. We sought to identify factors that influenced absolute lymphocyte count (ALC) nadir during chemoradiation therapy (CRT) for esophageal cancer (EC) and looked for clinically relevant associations with survival. METHODS AND MATERIALS: 504 patients with stage I-III EC (2007-2013) treated with neoadjuvant or definitive CRT with weekly ALC determinations made during treatment were analyzed. Grade of lymphopenia from ALC nadir during CRT was based on Common Terminology Criteria for Adverse Events version 4.0. Associations of ALC nadir with survival were examined using multivariate Cox proportional hazards analysis (MVA) and competing risks regression analysis. RESULTS: The median follow-up time was 36 months. The incidences of grade 1, 2, 3, and 4 ALC nadir during CRT were 2%, 12%, 59%, and 27%, respectively. The impact was lymphocyte-specific because this was not seen for monocyte or neutrophil count. On MVA, grade 4 ALC nadir (G4 nadir) was significantly associated with worse overall and disease-specific survival outcomes. Predictors of G4 nadir included distal tumor location, definitive CRT, taxane/5-fluorouracil chemotherapy, and photon-based radiation type (vs proton-based). Radiation type strongly influenced the mean body dose exposure, which was a strong predictor for G4 nadir (odds ratio 1.22 per Gray, P<.001). CONCLUSIONS: G4 nadir during CRT for EC was associated with poor outcomes, suggesting a role of host immunity in disease control. This observation provides a rationale to prospectively test chemotherapeutic and radiation treatment strategies that may have a lower impact on host immunity.
引用
- Davuluri R, Jiang W, Fang P, et al. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816138. doi:10.1016/j.ijrobp.2017.05.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。